Cell Therapy News

Researchers found lisocabtagene maraleucel to be a cost-effective second-line treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma, study findings published in Blood Advances showed.

The microbiome is linked to myriad processes in human health and disease.

Curative potential at a longer follow-up, logistics and patient risk and eligibility are all important considerations when sequencing bispecific antibodies and chimeric antigen receptor T-cell therapy for advanced large B-cell lymphoma.

The FDA placed a clinical hold on a trial designed to evaluate a novel cell therapy for non-small cell lung cancer after one study participant died.

In this episode, host Shikha Jain, MD, speaks with St. Jude’s Steven Gottschalk, MD, and Paulina Velasquez, MD, about the evolution of bone marrow transplant and cell therapy, increasing accessibility to CAR T-cell therapy and more.

SAN DIEGO — Infections are the main driver of mortality not related to disease relapse among individuals who received chimeric antigen receptor T cells, results of a meta-analysis presented at ASH Annual Meeting and Exhibition showed.

SAN DIEGO — All 38 patients with heavily pretreated multiple myeloma responded to an investigational chimeric antigen receptor T-cell therapy, results of a phase 1 study presented at ASH Annual Meeting and Exhibition showed.

SAN DIEGO — Patients with relapsed large B-cell lymphoma who achieved a complete remission had a reduced relapse rate and improved PFS with autologous transplant, according to study findings presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Individuals with private insurance that requires a signed agreement before receiving chimeric antigen receptor T cells had significant delays in treatment, study results presented at ASH Annual Meeting and Exposition showed.

Chimeric antigen receptor T cells have improved survival rates as second-line therapy for individuals with high-risk diffuse large B-cell lymphoma, but available therapies lack cost-effectiveness at current prices, study results showed.